SAN DIEGO, April 19, 2016 /PRNewswire/ -- ALSP, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims directed to a group of ALP-496-related compounds, which ALSP had earlier licensed from Columbia University.
Michael Pierschbacher, PhD, CEO, stated, "This issuance significantly increases the depth of our patent-approved pipeline of potential drug candidates."
About ALSP, Inc.
ALSP, Inc. is a privately held company in San Diego, California, developing small molecule drugs for treating neurodegenerative diseases, initially focused on TBI and Alzheimer's Disease (AD).
Further information: www.alspinc.com
This release contains "forward-looking statements" as defined under U.S. federal securities laws.
For More Information Contact:
Michael D Pierschbacher, CEO
Leslie V Barrett, Investor Relations
SOURCE American Life Science Pharmaceuticals, Inc.